Nord/LB Reiterates “Buy” Rating for Roche (ROG)

Nord/LB reissued their buy rating on shares of Roche (VTX:ROG) in a research note issued to investors on Tuesday.

Several other equities analysts have also commented on ROG. Goldman Sachs Group set a CHF 325 target price on shares of Roche and gave the company a buy rating in a report on Thursday, September 21st. JPMorgan Chase & Co. set a CHF 300 target price on shares of Roche and gave the company a buy rating in a report on Friday, December 29th. Kepler Capital Markets set a CHF 230 target price on shares of Roche and gave the company a neutral rating in a report on Monday, September 11th. Barclays set a CHF 305 target price on shares of Roche and gave the company a buy rating in a report on Wednesday, December 27th. Finally, Sanford C. Bernstein set a CHF 262 target price on shares of Roche and gave the company a buy rating in a report on Friday, December 1st. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of CHF 263.42.

Roche (ROG) opened at CHF 252.20 on Tuesday. Roche has a twelve month low of CHF 226.10 and a twelve month high of CHF 273. The company has a market cap of $217,410.00 and a price-to-earnings ratio of 22.42.

TRADEMARK VIOLATION NOTICE: “Nord/LB Reiterates “Buy” Rating for Roche (ROG)” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://transcriptdaily.com/2018/01/06/nord-lb-reiterates-buy-rating-for-roche-rog.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply